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Abstract
Background: Hemoglobin E beta-thalassemia (b-thalassemia/Hb E) has a variable severity, and the cost of
treatment has not been well studied. The aim of this study was to analyze the societal cost of caring for children
with b-thalassemias in Thailand. The study was designed as a prevalence-based cost-of-illness analysis in a societal
perspective. Medical records from three public hospitals of children aged 2-18 years with b-thalassemia/Hb E and
homozygous b-thalassemia were reviewed for direct medical cost determination. For direct non-medical cost and
indirect cost, a family member was interviewed.
Findings: It was found that 201 patients with b-thalassemia/Hb E (91%) and homozygous b-thalassemia (9%) were
recruited for this study. Ninety-two (46%) were severe thalassemia and 109 (54%) were mild to moderate severity.
The annual average cost of treatment was US$950; 59% was direct medical cost, 17% direct non-medical cost, and
24% indirect cost. The costs were differentiated by some potential predictors. Significant predictor variables were:
hospital, health insurance scheme, blood transfusion pattern, and iron chelation drug use.
Conclusions: The average annual cost per patient was calculated, and the cost model was estimated. These would
be applied for national planning, economic evaluation of treatment and prevention interventions, and budget
impact analysis.
Background
Beta-thalassemia (b-thalassemia) is a common inher-
ited blood disorder worldwide. Hemoglobin E/b-thalas-
semia is particularly common in Southeast Asia and
the Indian subcontinent, as well as coastal North
America, where Southeast Asian immigrants constitute
a substantial percentage of the population [1-3]. With
a population of 65 million, 7% with a b-thalassemia
trait and 17% with an HbE trait, an estimated 35,000
patients are living with b- t h a l a s s e m i as y n d r o m ei n
Thailand [4]. Hb E/b-thalassemia has a variable sever-
ity [5-7].
Studies on the economic burden of b-thalassemia have
been reported from the United Kingdom [8], Canada
[9], Israel, Taiwan, Sri Lanka [10], and Myanmar [11].
In Thailand, a study on the lifetime cost of homozygous
b-thalassemia in children was conducted in 2001, and
estimated the direct medical cost of treatment to be
6,660,000 Thai baht, or approximately US$149,899, over
a period of 30 years [12]. This cost estimate was based
on expert opinion, covering mainly blood transfusion
and iron chelation drugs. There is also a study on the
cost-benefits of prevention measures [13]. Based on our
knowledge, we have not found any cost-of-illness study
of thalassemia employing patient-specific cost data cov-
ering both direct and indirect costs in Thailand. We
therefore conducted a comprehensive study of the cost
of Hb E/b-thalassemia.
Methods
Cost-of-illness study design
This study was a prevalence-based cost-of-illness analy-
sis [14]. The prevalence-based approach measures the
economic burden of all patients caused by a disease in a
given period, usually for one year. This study was ana-
lyzed from a societal perspective, the broadest one
which includes all costs incurred by all members of
society, including the public and private sectors [15].
Please see the supplement file for the detail.
* Correspondence: pyarp@mahidol.ac.th
1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok,
Thailand
Riewpaiboon et al. BMC Research Notes 2010, 3:29
http://www.biomedcentral.com/1756-0500/3/29
© 2010 Riewpaiboon et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License http://creativecommons.org/licenses/by/2.0, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Study hospitals
In Thailand, public health facilities are major players in
the health delivery system, accounting for 80.5% of total
inpatient beds. For the public sector, there are 15 teach-
ing hospitals, 63 military hospitals, 25 regional hospitals,
70 general hospitals, and 723 community hospitals (sta-
tistics from 2004). The study hospitals were selected on
the basis of data accessibility and cooperation (personal
relationship among researchers). Study sites were Sara-
buri Hospital (SB), Phramongkutklao Hospital (PK), and
Chulalongkorn Hospital (CL). SB is a 680-bed public
regional hospital 108 km north-east of Bangkok. PK is a
1,200-bed military medical college, and CL is a 1,268-
bed teaching hospital, both located in Bangkok and
under the Thalassemia Registration Project. The inpati-
ent wards’ occupancy rates were 92% (SB), 75% (PK),
and 82% (CL). This study was approved by the ethics
committees of all study hospitals.
Patients and data collection
Thalassemia is defined by haemoglobin typing. The
study group was composed of children aged 2-18 years
with b-thalassemia/Hb E and thalassemia major during
the fiscal year 2005 (1 October 2004 to 30 September
2005). In this study, patients were classified as “severe”
if they met at least one of the following criteria: 1)
patients whose onset of anemia was before 2 years of
age, and whose first transfusion occurred before 4 years
of age; 2) patients who were diagnosed with homozy-
gous b-thalassemia; and 3) patients whose pre-transfu-
sion Hb level was less than 7 g/dL [7,16]. Type of
transfusion was classified by frequency of blood
Table 1 Patients’ characteristics
Hospital
Saraburi Phramongkutklao Chulalongkorn Total
Number 72 (35.8%) 42 (20.9%) 87 (43.3%) 201 (100%)
Age; mean years (SD) 9.24 (3.89) 11.38 (3.84) 8.86 (3.48) 9.52 (3.82)
Gender (N = 201)
Male 34 (47.2%) 24 (57.1%) 49 (56.3%) 107 (53.2%)
Female 38 (52.8%) 18 (42.9%) 38 (43.7%) 94 (46.8%)
Type of payment (N = 201)
Universal Coverage Scheme (UC) 66 (91.7%) 24 (57.1%) 33 (37.9%) 123 (61.2%)
Civil Servant Medical Benefit Scheme (CSMBS) 1 (1.4%) 12 (28.6%) 11 (12.6%) 24 (11.9%)
Out of pocket 5 (6.9%) 6 (14.3%) 43 (49.4%) 54 (26.9%)
Disease type (N = 201)
Beta-thal/Hb E 68 (94.4%) 37 (88.1%) 78 (89.7%) 183 (91.0%)
Homozygous beta-thalassemia 4 (5.6%) 5 (11.9%) 9 (10.3%) 18 (9.0%)
Severity (N = 200)
Severe 38 (52.8%) 14 (34.1%) 42 (48.3%) 94 (47.0%)
Non-severe 34 (47.2%) 27 (65.9%) 45 (51.7%) 106 (53.0%)
Splenectomy* (N = 201)
Yes 22 (30.6%) 19 (45.2%) 22 (25.3%) 63 (31.3%)
No 50 (69.4%) 23 (54.8%) 65 (74.7%) 138 (68.7%)
Type of blood transfusion (N = 198)
No 23 (31.9%) 8 (19.0%) 10 (11.9%) 41 (20.7%)
Occasional (1-5 times/year) 24 (33.3%) 1 (2.4%) 15 (17.9%) 40 (20.2%)
Low (6-12 times/year) 24 (33.3%) 22 (52.4%) 33 (39.3%) 79 (39.9%)
High (> 12 times/year) 1 (1.4%) 11 (26.2%) 26 (31.0%) 38 (19.2%)
Iron chelation (N = 201)
Desferrioxamine 3 (4.2%) 27 (64.3%) 48 (55.2%) 78 (38.8%)
No drug 69 (95.8%) 15(35.7%) 39 (44.8%) 123 (61.2%)
Ferritin level (N = 127)
≤ 2,500 ng/ml 16 (80.0%) 20 (58.8%) 41 (56.2%) 77 (60.6%)
> 2,500 ng/ml 4 (20.0%) 14 (41.2%) 32 (43.8%) 50 (39.4%)
Complications (N = 201)
Yes 5 (6.9%) 13 (31.0%) - 18 (9.0%)
No 67 (93.1%) 29 (69.0%) 87 (100.0%) 183 (91.0%)
* prevalence
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times/year); and occasional (1-5 times/year). Thalasse-
mia complications include symptoms resulting from tha-
lassemia (e.g., congestive heart failure due to anemia or
ascending cholangitis). Thes a m p l es i z er e q u i r e di nt h e
study was calculated using the formula by Altman [17].
According to the formula, the sample size should not be
smaller than ten times the total number of independent
variables. Because the number of potential predictor
variables in this study is 14 covering age, hospital, health
insurance scheme, type of disease, blood transfusion pat-
tern (none, low, occasional, or high), splenectomy, sever-
ity, iron chelation use, and complications - the sample
size required is 140. Medical records were reviewed for
direct medical cost determination. For direct non-medi-
cal cost and indirect cost, a family member was
interviewed.
Statistical and sensitivity analysis
Descriptive statistics were used to summarize the depen-
dent and independent variables. Stepwise multiple
regression analysis [18] was employed to analyze the
relationship between the cost (dependent variable) and
potential predictor variables (independent variables).
Please see the supplement file for the detail. (see Addi-
tional file 1)
Results
Demographic and clinical characteristics
Two hundred and one patients were included in the
study. The interview response rate was 100%. The com-
positions by hospitals were: 36% from Saraburi Hospital,
43% from Chulalongkorn Hospital, and 21% from Phra-
mongkutklao Hospital. Males slightly outnumbered
females in all hospitals except Saraburi. The patients’
average age was 9.52 years (SD = 3.82), and more than
half were registered under the Universal Health Cover-
age Scheme. The major type of the disease was b-thalas-
semia/Hb E (91%). Approximately 30% had undergone a
splenectomy. Around 80% received blood transfusions
during the study year. On the other hand, 61% did not
receive any iron chelation drug. Eighteen patients (9%)
Table 2 Average service utilization classified by type of services, patient characteristics, and hospitals
Outpatient Hospitalization Average length of stay
(days, SD)
Blood
Category service (visits, SD) (%) Per all patients Per hospitalized
patients
transfusion
(times, SD)
Desferrioxamine
(vials, SD)
Hospital
Saraburi (N = 72) 6.74 (3.31) 15 (20.8%) 0.68 (1.76) 3.27 (2.58) 3.69 (3.59) 3.43 (20.42)
Phramongkutklao
(N = 42)
9.76 (4.44) - - - 8.64 (5.74) 93.95 (105.41)
Chulalongkorn (N = 87) 11.05 (4.37) 7 (8.0%) 0.69 (3.48) 8.57 (9.74) 9.86 (5.44) 53.77 (82.50)
Disease type
Beta-thal/Hb E (N = 183) 8.86 (4.31) 20 (10.9%) 0.57 (2.64) 5.25 (6.39) 6.94 (5.57) 39.59 (79.17)
Homozygous beta-thal
(N = 18)
13.06 (4.30) 2 (11.1%) 0.22 (0.73) 2.00 (1.41) 12.06 (4.32) 90.33 (83.78)
Severity
Severe (N = 94) 10.41 (4.14) 16 (17.0%) 0.95 (3.53) 5.56 (7.07) 9.35 (4.93) 58.63 (89.75)
Nonsevere (N = 106) 8.26 (4.46) 6 (5.7%) 0.19 (0.92) 3.33 (2.25) 5.74 (5.72) 31.70 (70.03)
Ferritin level
≤ 2,500 ng/ml (N = 77) 10.60 (3.51) 5 (6.5%) 0.17 (0.80) 2.60 (2.07) 8.96 (4.55) 51.38 (88.92)
> 2,500 ng/ml (N = 50) 11.76 (3.91) 5 (10.0%) 1.20 (4.60) 12.00 (9.82) 11.24 (4.94) 96.02 (92.76)
Complications
Yes (N = 18) 11.83 (3.92) 3 (16.7%) 0.56 (1.54) 3.33 (2.52) 10.39 (4.84) 113.44 (123.39)
No (N = 183) 8.98 (4.44) 19 (10.4%) 0.54 (2.61) 5.21 (6.56) 7.10 (5.65) 37.32 (72.18)
Total 201 22 (10.9%) 201 22 201 201
Mean 9.23 n/a 0.54 4.95 7.40 44.13
Standard deviation (SD) 4.46 n/a 2.53 6.16 5.65 80.69
Median 9.00 n/a 0.00 3.00 8.00 0.00
95% CI
Lower 8.61 n/a 0.19 2.22 6.61 32.91
Upper 9.85 n/a 0.89 7.69 8.18 55.36
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Page 3 of 7had complications. The complications were: gallstones
(2 cases), heart failure (2 cases), autoimmune hemolytic
anemia (2 cases) and anti-Hepatitis B (anti Hbs) positive
(12 cases). Details are shown in Table 1.
Resource utilization and cost
As reported in Table 2, the patients received treatment
as outpatients nearly every month (9 times a year), with
11% being hospitalized. Blood transfusion was per-
formed at an average of 7.4 times per year. The iron
chelation drug used was desferrioxamine (by injection,
500 mg vial). Average use was 44 vials per year. How-
ever, resource utilization was quite different between
hospitals and by disease type. The number of outpatient
visits was in the range of 7-11 and 9-13 times a year for
different hospitals and different diagnoses, respectively.
The number of blood transfusions and hospitalizations
was also different. Patients at the regional hospital (Sara-
buri) received less treatment than those at the other two
hospitals located in Bangkok for most medical services
except for rate of hospitalization. Severe patients
received more treatment than non-severe patients.
Blood transfusions and iron chelation drugs used by
severe patients were approximately two times more than
those by non-severe patients. Similarly, patients with
complications consumed more resources than those
without complications.
Regarding costing, the numbers of individual medical
resources were multiplied by their unit costs. The unit
costs for frequently used drugs and laboratory investiga-
tions are presented in Table 3. The costs were converted
from Thai baht to US dollars at the rate of 40.22 baht
per US$1 (2005 prices) [19]. Costing results are pre-
sented in Table 4. Direct medical cost was separated
into cost incurred at the study hospitals, and other
health facilities including drug stores and alternative
medicine. For cost at the study hospitals, the iron-che-
lating drug (DFO) was shown separately from other
drugs. Routine service referred to cost of visits at outpa-
tient departments and hospital stays in wards. Each item
of cost and total cost were presented in the form of sub-
group analysis regarding hospital, disease type, severity,
ferritin level, and complications. For total cost from a
societal perspective, the average cost of patients at the
teaching hospital (Chulalongkorn) was US$1,297, three
times more than that of the public hospital (Saraburi).
Homozygous b-thalassemia had the highest cost (US
$1,434). Patients with severe conditions and complica-
tions had higher costs than those with non-severe con-
ditions and no complications. In terms of cost
composition, iron chelation drugs accounted for 39%,
followed by blood transfusion at 21% of the direct medi-
cal cost at the study hospitals. In sum, the cost of the
disease was composed of 59% direct medical cost, 17%
direct non-medical cost, and 24% indirect cost. Please
see the supplement files for the detail of sensitivity ana-
lysis and cost function. (see Additional file 1)
Discussion
Unlike thalassemia in European countries, a majority of
Thai thalassemia patients represented in this study are
of intermediate severity. Most children with severe tha-
lassemia in Thailand are under-treated by international
standards [16], as evidenced by pre-transfusion hemo-
globin below 7 g/dL. Few received iron chelation, and
all but very few patients received adequate iron chela-
tion. The choices of high or low transfusion are indivi-
dually determined by the treating physician, as well as
through compliance of the patient’s family. There are
differences in the practice of thalassemia treatment.
While the proportion of types and severity of thalasse-
mia in children were comparable among the three study
sites, one-quarter of patients treated in the medical
school received high transfusion, > 40% had high ferri-
tin, and more than half received iron chelation. In con-
trast, all but one patient at Saraburi received high
transfusion, only 20% had high ferritin, and < 5%
received iron chelation. It is therefore not surprising
that costs are significantly higher at medical centers in
Bangkok.
Table 3 Unit cost of drugs and medical services* (US$ at
2005 prices)
per 100 units per unit
Aspirin, enteric-coated tablet, 1 grain 0.47 n/a
Desferrioxamine injection, 500 mg 452.26 n/a
Deferasirox tablet, 250 mg 1243 n/a
Folic acid tablet, 5 mg 0.22 n/a
Furosemide injection, 20 mg/2 ml 11.64 n/a
Furosemide tablet, 40 mg 0.67 n/a
Multivitamin syrup, 60 ml 25.48 n/a
Multivitamin tablet 0.52 n/a
Penicillin V tablet, 250 mg 1.86 n/a
LPRC n/a 13.67
Pre-storage filtered PRC n/a 11.93
NAT LPRC n/a 21.13
NAT Prestorage filtered PRC n/a 19.39
Complete blood count (CBC) n/a 1.49
Cross-matching n/a 1.99
Ferritin n/a 7.71
Hematocrit (Hct) n/a 0.75
Hemoglobin (Hb) n/a 2.49
Hemoglobin typing n/a 6.71
LPRC = leukocyte-reduced packed red cell
Prestorage filtered PRC = leukocyte-depleted packed red cell (LDPRC)
NAT LPRC = nucleic acid-tested LPRC
* From the prices of services of health facilities under the Ministry of Public
Health [25].
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Page 5 of 7Although this study may have limitations on the
number of hospitals included, they do represent three
major health service settings: namely, public hospitals,
teaching hospitals, and military hospitals. In regard to
the representativeness of the patients, based on the
proportion of newborn thalassemia (thal): b-thal/Hb E,
homozygous b-thal, and Hb H disease constitute 30%,
6%, and 64%, respectively. Life spans of b-thal/Hb E,
homozygous b-thal, and Hb H disease patients are esti-
mated as 30 years, 10 years, and 60 years, respectively
[20,21]. The proportion of b-thal/Hb E to homozygous
b-thal was 5:1. By comparison, proportions of b-thal/
Hb E and homozygous b-thal in this study are 91%
and 9%, respectively (Table 1). The proportion of b-
thal/Hb E and homozygous b-thal was thus 10:1.
Therefore, the mean cost of the samples may not
represent that of the population. In addition, we con-
ducted a subgroup analysis. A weighted average techni-
que can be applied to calculate the mean cost of the
population [22]. Other studies used cost at charge or
incomplete cost items [11,23,24]. The cost composition
included in this analysis is the most complete, since it
covers material cost, labor cost and capital cost,
including the cost of patient care and non-patient care
activities [25]. However, it is a prevalence-based cost-
of-illness study, and therefore does not show the whole
picture as an incidence-based or lifetime cost of illness,
as do other studies. The lifetime cost of thalassemia is
presented elsewhere [8,9].
Direct medical cost was approximately 60% of the
total cost. Among the direct medical costs, iron chela-
tion drugs accounted for 39%. Iron chelation contri-
butes significantly to the cost of treatment. Adequate
iron chelation has been shown to reduce the complica-
tions related to thalassemia and iron overload, and
reduce the cost of treatment for these complications
[26]. Proportion of indirect cost would increase if we
can capture productivity loss due to a decrease of work-
ing capacity. In addition, it would be higher among
adult patients who are all in working age with higher
number of death. Please see the supplement files for the
detail of sensitivity analysis and cost function. (see
Additional file 2)
Conclusions
In conclusion, to our knowledge, this is the first time
that a complete cost-of-illness study of thalassemia has
been performed in Thailand. The results provided the
cost of taking care of child patients in a societal per-
spective, covering direct medical cost, direct non-medi-
cal cost, and indirect cost. The average annual cost per
patient was US$950. Direct medical cost accounted for
59% of the total cost. The costs were classified by hospi-
tal type, thalassemia type, severity, and complication.
The effects of blood type and iron chelation drug as
cost drivers were quantitatively explored. A cost model
was fitted; hospital, health insurance, blood transfusion
level, iron chelation drug use, and health insurance were
significant predictor variables.
Additional file 1: Additional methods, results and discussion. More
detail on costing methods, sensitivity analysis and cost function.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-0500-3-29-
S1.DOC]
Additional file 2: Table S1-S4. Results of sensitivity analysis and cost
function.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-0500-3-29-
S2.DOC]
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